NCT03575403View on ClinicalTrials.gov

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
Alcohol Use Disorder
Interventions
DRUG

Alcohol

In each arm and during sessions, subjects will receive doses of alcohol designed to raise breath alcohol levels (BAL) to 0.03 g/dl.

DRUG

Placebos

Subjects will receive oral placebo capsules.

DRUG

Duloxetine (60 MG)

Subjects will receive 60-mg of oral duloxetine capsules.

DRUG

Methylphenidate

Subjects will receive methylphenidate capsules.

DRUG

Duloxetine (30 MG)

Subjects will receive 30-mg of oral duloxetine capsules.

Trial Locations (1)

40511

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Craig Rush

OTHER

NCT03575403 - Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate) | Biotech Hunter | Biotech Hunter